Understand the source comparison
Best Peptides for IVF Support: Evidence Comparison
CJC-1295 + Ipamorelin Dual-pathway GH secretagogue. Pulsatile release preserves physiological rhythm Small Phase 2 trials show improved oocyte yield in poor responders; no large RCTs 200–250 mcg each peptide subcutaneously before bed, 10–12 weeks pre-retrieval
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- CJC-1295 + Ipamorelin
- Dual-pathway GH secretagogue. Pulsatile release preserves physiological rhythm
- Small Phase 2 trials show improved oocyte yield in poor responders; no large RCTs
- 200–250 mcg each peptide subcutaneously before bed, 10–12 weeks pre-retrieval
- Requires injection; no FDA approval for fertility indication
- Strongest mechanistic rationale and best preliminary data for oocyte quality improvement
- Thymalin
- Thymus-derived immune modulator. Increases Tregs and balances Th1/Th2 cytokines
- Observational studies in recurrent implantation failure show 2× implantation rate vs controls
- 10 mg IM daily for 10 days post-transfer
- Narrow treatment window; limited Western clinical validation
- Best option for women with immune-mediated implantation failure or elevated NK cells
- MK-677
- Oral ghrelin mimetic. Continuous GH/IGF-1 elevation
- Indirect evidence from metabolic studies; no direct IVF outcome trials
- 12.5 mg oral daily for 8–12 weeks pre-retrieval
- Causes insulin resistance and appetite increase; non-pulsatile stimulation
- Convenient but metabolically riskier. Use only in women with low baseline IGF-1 and normal glucose tolerance
- Cerebrolysin
- Neurotrophic peptide complex. Limited reproductive data
- No direct IVF studies; speculative use based on mitochondrial support in neuronal models
- Not established for IVF protocols
- Mechanism not well-characterized in reproductive tissue
- Insufficient evidence to recommend for fertility enhancement